Daniel W. Muehl

Daniel W. Muehl discloses dealings in 2 companies, chiefly Clovis Oncology, Inc. and Repligen Corp. We count 140 filings; the first trade dates from 19 January 2006 and the latest from 2 November 2022.

Sales make up the whole of the open-market record (59 sales, €392k). The rest of the record consists of 12 share grants and 69 option exercises. In 2022 alone, the filings show no purchases and 12 sales.

Most recently, on 3 November 2022, the filings show an open-market sale worth €2,056 in Clovis Oncology, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.